Bfl-1-IN-7
Bfl-1-IN-7 is an orally active and selective Bfl-1 inhibitor with an IC50 value of 0.015 μM. Bfl-1-IN-7 activates caspase 3/7, and when combined with the Mcl-1 inhibitor AZD5991 (HY-101533), it reduces the viability of lymphoma cells. Bfl-1-IN-7 can be used in lymphoma-related studies.
For research use only. We do not sell to patients.
- Formula: C24H26F3N3O3
- Molecular Weight:461.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Bfl-1 0.015 μM (IC50) |
Caspase-3 |
Caspase-7 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SU-DHL-1 | EC50 |
0.31 μM
|
Induction of caspase activation (a marker of apoptosis) in SU-DHL-1 lymphoma cells when combined with Mcl-1 inhibitor AZD5991, measured after 6-hour incubation.
Induction of caspase activation (a marker of apoptosis) in SU-DHL-1 lymphoma cells when combined with Mcl-1 inhibitor AZD5991, measured after 6-hour incubation.
|
41432228 |
| SU-DHL-1 | EC50 |
0.21 μM
|
Reduction of SU-DHL-1 lymphoma cell viability measured after 24-hour incubation.
Reduction of SU-DHL-1 lymphoma cell viability measured after 24-hour incubation.
|
41432228 |
| KARPAS-422 | EC50 |
>10 μM
|
Lack of cell viability reduction in Bfl-1-null Karpas-422 cells, with no effect observed at concentrations up to 10 μM after 24-hour incubation.
Lack of cell viability reduction in Bfl-1-null Karpas-422 cells, with no effect observed at concentrations up to 10 μM after 24-hour incubation.
|
41432228 |
In Vitro
Bfl-1-IN-7 (compound 25) potently and selectively inhibits purified Bfl-1 protein with an IC50 of 0.015 μM. When combined with the Mcl-1 inhibitor AZD5991 (HY-101533), it induces caspase activation in SU-DHL-1 lymphoma cells with an EC50 of 0.31 μM[1].
Bfl-1-IN-7 (0.2-20 μM; 4 h) covalently labels the C55 residue of Bfl-1 in LY10 lymphoma cells in a dose-dependent and selective manner, with extremely low off-target activity against BTK C481[1].
Bfl-1-IN-7 potently inhibits Bfl-1 in biochemical FRET assays, with a mean pIC50 of 7.809; in combination with AZD5991, it induces caspase 3/7 activation in SU-DHL-1 cells, with a mean pEC50 of 6.503[1].
Bfl-1-IN-7 covalently binds to purified Bfl-1 in a concentration- and time-dependent manner, and its observed rate constant increases with the elevation of compound concentration[1].
Bfl-1-IN-7 reduces the viability of SU-DHL-1 lymphoma cells, with an EC50 of 0.21 μM at 24 h[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
Chemical Information
-
Molecular Weight 461.48
-
Formula C24H26F3N3O3
-
SMILES
C=CC(N([C@@H](C)C1=CC=C(NC([C@@H]2CCC[C@H]2N)=O)C=C1)C3=CC=C(OC(F)(F)F)C=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)